CPT® Code 0630T

Official Description

Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)

Common Language Description

The CPT® Code 0630T refers to a specific medical procedure involving the percutaneous injection of allogeneic cellular and/or tissue-based products into the intervertebral disc. Allogeneic cells, often referred to as universal cells, are derived from a single source, such as umbilical cord blood, and are stored in a master cell bank. These cells are processed for specific therapeutic applications, particularly in the treatment of intervertebral disc degeneration. The procedure aims to provide pain relief and enhance the quality of the disc without resorting to invasive surgical methods, making it a less invasive alternative to autologous cell therapy, which uses the patient's own cells. During the procedure, local anesthesia is administered, and imaging guidance, such as computed tomography (CT), is utilized to ensure precise placement of the injection. The injection consists of a ready-to-use material containing a predetermined number of cells per segment being treated. This procedure can be performed unilaterally or bilaterally, depending on the clinical need. It is important to note that this code is specifically for reporting each additional level of injection beyond the primary procedure, which is reported separately using other designated codes. The use of imaging guidance is crucial for the accuracy and effectiveness of the injection, ensuring that the therapeutic agents are delivered precisely to the targeted area within the lumbar intervertebral disc.

1. Indications

The procedure described by CPT® Code 0630T is indicated for the treatment of intervertebral disc degeneration. This condition may present with various symptoms, including but not limited to:

Chronic Back Pain Persistent pain in the lower back that may be associated with disc degeneration.
Radiculopathy Pain that radiates down the legs due to nerve root compression caused by degenerated discs.
Reduced Mobility Limitations in movement and flexibility due to pain and discomfort in the lumbar region.
Disc Herniation Conditions where the intervertebral disc bulges or ruptures, potentially leading to nerve compression.

2. Procedure

The procedure involves several key steps to ensure effective delivery of the allogeneic cellular and/or tissue-based product into the intervertebral disc. Each step is critical for the success of the treatment:

Preparation The patient is positioned appropriately, and the area of injection is identified using imaging guidance. Local anesthesia is administered to minimize discomfort during the procedure.
Imaging Guidance CT imaging is utilized to provide real-time visualization of the lumbar spine, ensuring accurate targeting of the intervertebral disc for injection.
Injection A percutaneous approach is taken to inject the prepared allogeneic cellular product into the intervertebral disc. The injection may be performed unilaterally or bilaterally, depending on the clinical indication and the number of levels being treated.
Post-Injection Monitoring After the injection, the patient is monitored for any immediate adverse reactions and to assess the effectiveness of the procedure.

3. Post-Procedure

Post-procedure care involves monitoring the patient for any potential side effects or complications following the injection. Patients may experience some discomfort at the injection site, which is typically managed with standard pain relief measures. It is essential for patients to follow any specific post-procedure instructions provided by their healthcare provider, which may include activity restrictions and follow-up appointments to evaluate the effectiveness of the treatment. Recovery time can vary, but many patients may resume normal activities shortly after the procedure, depending on their individual response and the extent of the treatment performed.

Short Descr	PERQ NJX ALGC CT LMBR EA
Medium Descr	PERQ NJX ALGC CELL&/PRDCT UNI/BI CT LMBR EA
Long Descr	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)
Status Code	Carriers Price the Code
Global Days	ZZZ - Code Related to Another Service
PC/TC Indicator (26, TC)	0 - Physician Service Code
Multiple Procedures (51)	0 - No payment adjustment rules for multiple procedures apply.
Bilateral Surgery (50)	2 - 150% payment adjustment does NOT apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	0 - Payment restriction for assistants at surgery applies to this procedure...
Co-Surgeons (62)	0 - Co-surgeons not permitted for this procedure.
Team Surgery (66)	0 - Team surgeons not permitted for this procedure.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Items and Services Packaged into APC Rates
ASC Payment Indicator	Packaged service/item; no separate payment made.
Berenson-Eggers TOS (BETOS)	none
MUE	4

This is an add-on code that must be used in conjunction with one of these primary codes.

0629T

MPFS Status: Carrier Priced APC J1 ASC J8 Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level